Non-Hodgkin’s Lymphoma

Although the R-CHOP regimen has significantly improved the prognosis for most patients, a subset continues to experience poor therapeutic outcomes...The key gene TRPV2, associated with favorable prognosis, was found to promote M1-like polarization in monocytes/macrophages and enhance antigen presentation in B cells. This study establishes the NR risk score as a novel prognostic tool for DLBCL and underscores neuro-immune interactions as potential therapeutic targets.

Our analysis delineates a plausible link between DIGs and DLBCL outcome, nominating CCT5 as environmentally relevant biomarkers with prognostic and potential therapeutic implications.

Pathology confirmed a mixed ductal-neuroendocrine-acinar cell carcinoma in the pancreas and a diffuse large B-cell lymphoma in the kidney and lymph nodes. Pancreatic MiNEN is an extremely rare disease, accounting for only about 0.2% of all pancreatic tumors.

P1, N=20, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

P2, N=30, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

P1, N=17, Active, not recruiting, Byondis B.V. | Recruiting --> Active, not recruiting | N=100 --> 17 | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Oct 2025 --> Feb 2026

P3, N=80, Enrolling by invitation, Second Affiliated Hospital of Nanchang University

Co-existent PTC, immunopositivity for thyroid-differentiation markers, and the genetic profile confirm a squamoglandular metaplasia of follicular cells as the origin. The absence of MAML2 fusion questions its WHO categorization as a "salivary gland-type carcinoma." Detailed molecular profiling, while contributing to a better understanding of the pathogenesis of this enigmatic neoplasm, also helped decipher potentially actionable genetic variants.

Further, strong constitutive NF-κB activation overcomes critical microenvironmental dependencies of TCL1-driven lymphomas. Our findings establish canonical NF-κB as an oncogenic driver in lymphoma and reveal reduced microenvironment dependency as a key NF-κB-mediated mechanism, thus highlighting its therapeutic relevance.

P2, N=1376, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> Jan 2027

Kaplan-Meier analysis of R-CHOP-treated patients with DLBCL-NOS revealed that those with MCD, BN2, and A53 subtypes had poorer overall survival than those with EZB and ST2, particularly among patients with concurrent MYC/BCL2 DE. Using a clinically applicable NGS panel, we successfully implemented the LymphGen classification system. This study underscores the distinct genetic landscape of Korean DLBCL and highlights the utility of LymphGen in identifying high-risk subgroups, providing a basis for prognostic stratification and therapeutic optimization.

Furthermore, the mutational and transcriptomic profiles of the late-onset del8 pBLs were reminiscent of human activated B-cell-like diffuse large B-cell lymphoma (DLBCL) whereas those of the del19 pBLs resembled germinal center B-cell-like DLBCL. These results establish the molecular signatures in radiation-induced pBLs that depend on radiation type, which will help improve both targeted molecular therapies for patients and risk assessment after exposure.